Clinical presentations of soft-tissue infections and surgical site infections

Clinical Infectious Diseases

Volumn 33, Issue 5 SUPPL. 2, 2001, Pages

  Nichols, R L ^a   Florman, S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

CLINICAL FEATURE; CONFERENCE PAPER; DEBRIDEMENT; ESTHETIC SURGERY; LIFESTYLE; PLASTIC SURGERY; PRIORITY JOURNAL; SOFT TISSUE INFECTION; SURGICAL INFECTION;

EID: 0035451826     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321862     Document Type: Conference Paper

References (26)

1. Postoperative infection in the age of drug-resistant gram-positive bacteria
2. The nationwide nosocomial infection rate: A new need for vital statistics
3. Clostridial sepsis: Usual clinical presentations
4. Severe systemic sepsis resulting from neglected perineal infections
5. Ecthyma gangrenosum: A deadly complication
6. Preventing surgical site infections: A surgeon's perspective
7. CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections
8. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996: A report from the National Nosocomial Infections Surveillance (NNIS) System
9. Resistant gram-positive organisms
10. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
11. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin
12. Management of bacterial complications in critically ill patients: Surgical wound and catheter-related infections
13. Gram-positive resistance: Challenge for the development of new antibiotics
14. Antibiotics for gram-positive bacterial infections: Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid
15. Nosocomial vancomycin-resistant enterococci in the United States, 1989-1995: The first 1000 isolates
16. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
17. Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997
18. Update: Staphylococcus aureus with reduced susceptibility to vancomycin: United States, 1997
19. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
20. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus
21. Anti-gram-positive agents: What we have and what we would like
22. Red man syndrome
23. Quinupristin/dalfopristin: A review of its use in the management of serious gram-positive infection
24. The efficacy and safety of quinupristin/dalfopristin (Synercid) for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
25. Linezolid